Personalized Medicine
Play video

Personalized Medicine

PREDYSTIC® Infliximab RA Kit

Future therapies rely on the development of Personalized Medicine, when the therapy is tailored to the patient’s anatomy, metabolism, biochemistry thus the genetic fingerprint of the individual.

The core of Personalized Medicine is the observation that we can understand the unique nature of the actual patient based on genetic, epigenetic, and clinical information. Thus, we can predict, diagnose or cure them tailored to their individual needs.

The essence of Personalized Medicine is a reliable diagnostic method connecting the individual interaction between the patient and the medication, facilitating the selection of the effective therapy, reducing side-effects thus supporting the realization of a cost-effective therapy as well.

Egis Pharmaceuticals PLC has started its journey in the Personalized Medicine space by developing a novel innovative diagnostic method, the PREDYSTIC® Infliximab RA Kit complying with the effective European In-vitro Diagnostic Directive (IVDD) and also in line with the future In-vitro Diagnostic Regulation (IVDR) requirements.

In rheumatoid arthritis (RA) the therapeutic response shows significant differences between individuals thus it is important to have a complementary diagnostic, predicting the therapeutic response before treatment initiation.

The development of PREDYSTIC® Infliximab RA Kit has covered the complete cycle from biomarker discovery to successful clinical performance evaluation and registration. The diagnostic test identifies those bio-naïve patients with RA, who are likely responders or non-responders to infliximab treatment based on the biomarker analysis of day zero blood sample.

Egis Pharmaceuticals PLC as the official manufacturer of the PREDYSTIC® Infliximab RA Kit received the CE In-vitro Diagnostic (IVD) Medical Device Certificate in December 2020.

The PREDYSTIC® Infliximab RA Kit will be available from September 2021 as a Product and as a Service via our official partners. Please send your questions and inquiries to the predystic@egis.hu e-mail address.

For more information on the PREDYSTIC® Infliximab RA Kit please scroll down and visit the Clinical need / Development / Clinical Performance Evaluation sections.

For the latest information, visit the Linkedin page of the PREDYSTIC® Infliximab RA Kit.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox